Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Drugs and Medicinal Substances

Lidocaine

Nervous System Agents

Lidocaine is a local anesthetic of the amino amide type, typically taking effect within several minutes and lasting from half an hour to three hours, and it is also used as a class Ib antiarrhythmic medication to treat ventricular tachycardia and ventricular fibrillation. As a local anesthetic it blocks nerves from conducting signals to or from the brain; as an antiarrhythmic it blocks sodium channels in the heart, slowing the rate of contractions. A team led by chemist Nils Lofgren first synthesized the compound under the name xylocaine in 1943, with Inga Fischer credited as the first to synthesize it at large scale, and the Swedish company Astra first marketed it in 1948, making it the first amino amide-type local anesthetic. Lidocaine appears on the World Health Organization's List of Essential Medicines.

Facts
Drug Class
Local anesthetic of the amino amide type 1
Mechanism of Action
Alters signal conduction in neurons by prolonging the inactivation of the fast voltage-gated sodium channels in the neuronal cell membrane responsible for action potential propagation 1
Approved Use
Ventricular tachycardia and ventricular fibrillation, in addition to use as a local anesthetic 1
First Approved / Isolated Year
1948 1
Significant Risk
Overdose can lead to severe toxicity or death (local anesthetic systemic toxicity) 1
Classification
Approval Status
Approved 1
ATC ClassSourced to the subject's own account
N: Nervous System 2
Route of Administration
Intravenous 1
WHO Essential MedicineSourced to the subject's own account
Core List 3
Sources
1. Lidocaine - Wikipedia
  • Lead section, first sentence
    is a local anesthetic of the amino amide type
  • Article body, sentence beginning 'Lidocaine alters signal conduction in neurons'
    Lidocaine alters signal conduction in neurons by prolonging the inactivation of the fast voltage-gated Na+ channels in the neuronal cell membrane responsible for action potential propagation.
  • Lead section, second sentence
    It is also used to treat ventricular tachycardia and ventricular fibrillation.
  • Article body, sentence beginning 'It was first marketed in 1948'
    It was first marketed in 1948 by Astra.
  • Article body, sentence beginning 'Such overdoses have often led to severe toxicity'
    Such overdoses have often led to severe toxicity or death in both children and adults (local anesthetic systemic toxicity).
  • Lead section, route-of-administration statement
    If injected intravenously, it may cause cerebral effects such as confusion, changes in vision, numbness, tingling, and vomiting.
  • Regulatory approval status
View the Source
2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code N
Quote, First-level anatomical group codes, Code N
Nervous system
View the Source
3. WHO Model List of Essential Medicines (Wikipedia)
WikipediaWHO Model List of Essential Medicines, Antiarrhythmic medicines section
Quote, WHO Model List of Essential Medicines, Antiarrhythmic medicines section
Lidocaine
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.